Motilal Oswal ne unlisted company Symbiotec Pharmalab ko cover karna shuru kiya hai. Brokerage ne stock ke liye **₹1,430** ka target set kiya hai, kyunki company ab steroid API se shift hokar high-margin CDMO aur injectables mein entry le rahi hai.
Badlav ki lehar: Kya hai Symbiotec ka plan?
Motilal Oswal ne Symbiotec Pharmalab ke liye ₹1,430 ka target price fix kiya hai. Ab tak ye company steroid aur hormone API market mein king bani hui thi, lekin ab ye CDMO (Contract Development and Manufacturing Organization) aur complex injectables ke sector mein bade kadam utha rahi hai.
Business Model mein bada jump
Company ab sirf purane products par depend nahi rehna chahti. Wo fermentation technology aur double-chamber vial manufacturing mein invest kar rahe hain. Brokerage ka manna hai ki ye shift company ko global markets, khaaskar United States mein bada revenue dilane mein madad karega.
Valuation aur Future Outlook
Brokerage ne company ko 35x forward earnings par value kiya hai. Ye premium valuation tabhi justify hogi jab company apne naye manufacturing setup ko sahi se operate kar paayegi. Sabse bada hurdle USFDA approvals honge, jo is industry mein game changer hote hain.
Kya Investors ko cautious rehna chahiye?
Dekhiye, CDMO space mein competition bahut tough hai. Naye facilities ko commission karna aur capacity utilization badhana asaan nahi hota. Agar regulatory delays hue ya US market mein expected contracts nahi mile, toh margins par pressure aa sakta hai. Also, yaad rakhein ki ye unlisted share hai, toh yahan liquidity ki thodi problem ho sakti hai. Hamesha apna homework karke hi invest karein!